An investigator initiated phase II clinical trial of Tamibarotene (AM80G) for chronic graft-versus-host disease
Phase of Trial: Phase II
Latest Information Update: 02 Mar 2017
At a glance
- Drugs Tamibarotene (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 28 Feb 2017 Status changed from active, no longer recruiting to discontinued.
- 27 Dec 2016 Status changed from recruiting to active, no longer recruiting.
- 20 May 2016 New trial record